Inhibition of O-GlcNAcase in perfused rat hearts by NAG-thiazolines at the time of reperfusion is cardioprotective in an O-GlcNAc-dependent manner

American Journal of Physiology - Heart and Circulatory Physiology - Tập 299 Số 5 - Trang H1715-H1727 - 2010
Boglárka Laczy1,2, Susan A. Marsh1, Charlye A Brocks1, István Wittmann2, John C. Chatham1
1Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama; and
2Faculty of Medicine, Second Department of Medicine and Nephrological Center, University of Pecs, Pecs, Hungary

Tóm tắt

Acute increases in O-linked β- N-acetylglucosamine ( O-GlcNAc) levels of cardiac proteins exert protective effects against ischemia-reperfusion (I/R) injury. One strategy to rapidly increase cellular O-GlcNAc levels is inhibition of O-GlcNAcase (OGA), which catalyzes O-GlcNAc removal. Here we tested the cardioprotective efficacy of two novel and highly selective OGA inhibitors, the NAG-thiazoline derivatives NAG-Bt and NAG-Ae. Isolated perfused rat hearts were subjected to 20 min global ischemia followed by 60 min reperfusion. At the time of reperfusion, hearts were assigned to the following four groups: 1) untreated control; 2) 50 μM NAG-Bt; 3) 100 μM NAG-Bt; or 4) 50 μM NAG-Ae. All treatment groups significantly increased total O-GlcNAc levels ( P < 0.05 vs. control), and this was significantly correlated with improved contractile function and reduced cardiac troponin I release ( P < 0.05). Immunohistochemistry of normoxic hearts showed intense nuclear O-GlcNAc staining and higher intensity at Z-lines with colocalization of O-GlcNAc and the Z-line proteins desmin and vinculin. After I/R, there was a marked loss of both cytosolic and nuclear O-GlcNAcylation and disruption of normal striated Z-line structures. OGA inhibition largely preserved structural integrity and attenuated the loss of O-GlcNAcylation; however, nuclear O-GlcNAc levels remained low. Immunoblot analysis confirmed ∼50% loss in both nuclear and cytosolic O-GlcNAcylation following I/R, which was significantly attenuated by OGA inhibition ( P < 0.05). These data provide further support for the notion that increasing cardiac O-GlcNAc levels by inhibiting OGA may be a clinically relevant approach for ischemic cardioprotection, in part, by preserving the integrity of O-GlcNAc-associated Z-line protein structures.

Từ khóa


Tài liệu tham khảo

10.1167/iovs.03-0227

10.1161/01.RES.0000137171.97172.d7

10.1016/j.bbagen.2009.07.018

10.1152/ajpcell.00162.2006

10.1152/ajpcell.00456.2007

10.1074/jbc.M303810200

10.1152/ajpendo.90281.2008

10.1042/BST0320831

10.1016/j.lfs.2009.01.007

10.1152/ajpcell.00422.2006

10.1152/ajpheart.01091.2006

10.2174/157436210790226537

10.1152/ajpheart.00816.2005

10.1161/01.RES.0000165478.06813.58

10.1074/jbc.M808518200

10.1016/j.hlc.2008.08.006

10.1161/CIRCULATIONAHA.107.730515

10.1023/A:1009813621103

10.1152/ajpheart.01056.2008

10.1016/j.yjmcc.2006.09.015

10.1152/ajpheart.00285.2007

10.1016/j.yjmcc.2005.11.003

10.1242/dmm.003855

10.1074/jbc.M804525200

10.1074/jbc.M413819200

10.1042/BJ20041506

10.1152/physrev.00024.2007

10.1097/CCM.0b013e3181cb10b3

10.2337/diabetes.53.4.1074

10.1074/jbc.M207787200

10.1161/01.RES.0000116143.74830.A9

10.1016/0022-2828(95)90016-0

10.1016/S0300-9084(01)01305-0

10.1074/jbc.M503396200

10.1016/j.cell.2007.03.022

10.1161/01.RES.60.4.478

10.1161/01.CIR.101.25.2874

10.1124/jpet.106.115519

10.1161/01.CIR.0000162466.06150.D4

10.1152/ajpheart.00144.2006

10.1152/ajpheart.00525.2002

10.1056/NEJMra071667

10.1038/nchembio.96

10.1016/j.bbalip.2006.04.007

10.1074/jbc.M403773200

Thông tin
Thông tin xuất bản

American Journal of Physiology - Heart and Circulatory Physiology

Tập 299 Số 5

H1715-H1727

Thông tin tác giả